BR0311176A - Formas pseudopolimórficas de um inibidor da protease do hiv - Google Patents

Formas pseudopolimórficas de um inibidor da protease do hiv

Info

Publication number
BR0311176A
BR0311176A BR0311176-8A BR0311176A BR0311176A BR 0311176 A BR0311176 A BR 0311176A BR 0311176 A BR0311176 A BR 0311176A BR 0311176 A BR0311176 A BR 0311176A
Authority
BR
Brazil
Prior art keywords
protease inhibitor
hiv protease
pseudopolymorphic forms
forms
pseudopolymorphic
Prior art date
Application number
BR0311176-8A
Other languages
English (en)
Other versions
BRPI0311176B1 (pt
BRPI0311176B8 (pt
Inventor
Hans Wim Pieter Vermeersch
Daniel Joseph Christiaan Thone
Luc Donne Marie-Louis Janssens
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0311176(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BR0311176A publication Critical patent/BR0311176A/pt
Publication of BRPI0311176B1 publication Critical patent/BRPI0311176B1/pt
Publication of BRPI0311176B8 publication Critical patent/BRPI0311176B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"FORMAS PSEUDOPOLIMóRFICAS DE UM INIBIDOR DA PROTEASE DO HIV". A presente invenção refere-se a novas formas pseudopolimórficas de (3R,3aS,6aR)-hexahidrofuro[2,3-b] furan-3-il (1S,2R)-3-[[(4aminofenil) sulfonil] (isobutil) amino]-1-benzil-2-hidroxipropilcarbamato e processos para a produção das mesmas.
BRPI0311176A 2002-05-16 2003-05-16 pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica BRPI0311176B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02076929.5 2002-05-16
EP02076929 2002-05-16
PCT/EP2003/050176 WO2003106461A2 (en) 2002-05-16 2003-05-16 Pseudopolymorphic forms of a hiv protease inhibitor

Publications (3)

Publication Number Publication Date
BR0311176A true BR0311176A (pt) 2005-03-15
BRPI0311176B1 BRPI0311176B1 (pt) 2019-08-20
BRPI0311176B8 BRPI0311176B8 (pt) 2021-05-25

Family

ID=29724454

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0311176A BRPI0311176B8 (pt) 2002-05-16 2003-05-16 pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica

Country Status (26)

Country Link
US (8) US7700645B2 (pt)
EP (4) EP3045460B1 (pt)
JP (1) JP4864320B2 (pt)
KR (2) KR101128370B1 (pt)
CN (1) CN100475819C (pt)
AP (1) AP2052A (pt)
AU (2) AU2003271740B2 (pt)
BR (1) BRPI0311176B8 (pt)
CA (1) CA2485834C (pt)
CY (3) CY1117928T1 (pt)
DK (3) DK2314591T4 (pt)
EA (1) EA007120B8 (pt)
ES (4) ES2638412T3 (pt)
HK (1) HK1081969A1 (pt)
HR (1) HRP20041061B1 (pt)
HU (1) HUE034389T2 (pt)
IL (1) IL165140A0 (pt)
LT (1) LT2767539T (pt)
MX (1) MXPA04011427A (pt)
NO (1) NO331477B1 (pt)
NZ (1) NZ536497A (pt)
PL (1) PL215151B1 (pt)
PT (3) PT1567529E (pt)
SI (3) SI1567529T2 (pt)
WO (1) WO2003106461A2 (pt)
ZA (1) ZA200410154B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1088098T4 (en) 1998-06-23 2015-09-14 Us Of America Represented By The Secretary Dept Of Health And Human Services Fitnessassay and methods for reducing HIV resistance to therapy
LT2767539T (lt) * 2002-05-16 2017-09-25 Janssen Sciences Ireland Uc Pseudopolimorfinės živ proteazės inhibitorių formos
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
UA85567C2 (en) 2003-12-23 2009-02-10 Тиботек Фармасьютикелз Лтд. Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate
BRPI0607827B8 (pt) 2005-02-25 2021-05-25 Janssen R & D Ireland composto precursor de inibidor de protease, processo para a produção do referido composto e seu uso
PL2089371T3 (pl) * 2006-11-09 2011-06-30 Janssen Sciences Ireland Uc Sposoby wytwarzania heksahydrofuro[2,3-b]furan-3-olu
TWI482775B (zh) 2008-09-01 2015-05-01 Tibotec Pharm Ltd 用於製備（３ｒ，３ａｓ，６ａｒ）－六氫呋喃并〔２，３－ｂ〕呋喃－３－基（１ｓ，２ｒ）－３－〔〔（４－胺基苯基）磺醯基〕（異丁基）胺基〕－１－苯甲基－２－羥基丙基胺基甲酸酯之方法
US20120035142A1 (en) * 2009-01-29 2012-02-09 Mapi Pharma Limited Polymorphs of darunavir
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
ES2619562T3 (es) * 2009-09-17 2017-06-26 Mylan Laboratories Limited Procesos para la preparación de darunavir y su forma amorfa
JP2013509400A (ja) * 2009-10-30 2013-03-14 ルパン リミテッド ダルナビルの新規調製方法および微粒子径のダルナビルエタノール付加物
CN102686594A (zh) * 2009-12-16 2012-09-19 熙德隆研究基金会 地瑞那韦的多晶型物
AU2010340799B2 (en) * 2010-01-05 2015-06-11 Cipla Limited Darunavir polymorph and process for preparation thereof
CA2784398A1 (en) 2010-01-28 2011-08-04 Mapi Pharma Limited Process for the preparation of darunavir and darunavir intermediates
PT2571355T (pt) * 2010-05-20 2016-10-17 Hetero Research Foundation Sal de cloridrato cristalino de darunavir
WO2012107889A1 (en) 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Process for the preparation of amorphous darunavir
SI2729130T1 (en) 2011-07-07 2018-03-30 Janssen Sciences Ireland Uc Combined formulations of darunavir
US9216990B2 (en) 2011-12-05 2015-12-22 Mylan Labs Limited Crystalline Darunavir
WO2013108105A2 (en) * 2012-01-18 2013-07-25 Aurobindo Pharma Limited Novel solvates of darunavir
CN103509031B (zh) * 2012-06-20 2016-04-27 上海迪赛诺药业有限公司 制备达芦那韦无定形物的方法
ES2848216T3 (es) * 2012-07-24 2021-08-05 Laurus Labs Ltd Un proceso para la preparación de Darunavir
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US9346820B2 (en) * 2013-09-11 2016-05-24 Purdue Research Foundation HIV-1 protease inhibitors having gem-di-fluoro bicyclic P2-ligands
WO2016092525A1 (en) * 2014-12-12 2016-06-16 Lupin Limited Darunavir n-propanol solvate and process for preparation thereof
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
HUE059771T2 (hu) 2015-03-19 2022-12-28 Mycovia Pharmaceuticals Inc Gombaellenes vegyületek és eljárások azok elõállítására
BR112019002120A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composição anti-retroviral de várias classes
EP3496718A4 (en) 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
US10407438B2 (en) 2016-10-27 2019-09-10 Gilead Sciences, Inc. Crystalline forms of darunavir
CN108727401A (zh) * 2017-04-20 2018-11-02 盐城迪赛诺制药有限公司 达鲁那韦新晶型及其制备方法和应用
CN109053753A (zh) * 2018-08-05 2018-12-21 浙江大学 一种制备达卢那韦二水合物晶型的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
JPH05230044A (ja) 1992-02-21 1993-09-07 Hoechst Japan Ltd ピレタニドの新規な結晶多形
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
ES2127938T3 (es) 1993-08-24 1999-05-01 Searle & Co Hidroxietilamino sulfonamidas utiles como inhibidores de proteasas retroviricas.
EP0812320B1 (en) * 1995-02-22 2000-07-12 Hoechst Pharmaceuticals & Chemicals K.K. Amorphous piretanide, piretanide polymorphs, process for their preparation and their use
CO4940492A1 (es) * 1997-05-29 2000-07-24 Merck & Co Inc Inhibidor de proteasa de vih
GB9712253D0 (en) 1997-06-13 1997-08-13 Glaxo Group Ltd Antiviral compound
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
GB9805898D0 (en) * 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
DK1088098T4 (en) 1998-06-23 2015-09-14 Us Of America Represented By The Secretary Dept Of Health And Human Services Fitnessassay and methods for reducing HIV resistance to therapy
AU4828199A (en) * 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
AU1735000A (en) 1998-11-19 2000-06-05 Du Pont Pharmaceuticals Company Crystalline (-)-6- chloro-4- cyclopropylethynyl- 4-trifluoromethyl- 3,4-dihydro-2(1h)-quinazolinone
PT1159278E (pt) 1999-02-12 2006-06-30 Vertex Pharma Inibidores de aspartil-protease
LT2767539T (lt) * 2002-05-16 2017-09-25 Janssen Sciences Ireland Uc Pseudopolimorfinės živ proteazės inhibitorių formos
AU2010340799B2 (en) * 2010-01-05 2015-06-11 Cipla Limited Darunavir polymorph and process for preparation thereof

Also Published As

Publication number Publication date
WO2003106461A3 (en) 2004-05-13
SI2767539T1 (sl) 2017-10-30
DK1567529T3 (da) 2014-09-15
NO20045409L (no) 2004-12-10
US20050250845A1 (en) 2005-11-10
AP2004003191A0 (en) 2004-12-31
ES2728735T3 (es) 2019-10-28
DK2314591T4 (da) 2021-05-10
EP2314591A1 (en) 2011-04-27
HK1081969A1 (en) 2006-05-26
EP2314591B2 (en) 2021-02-24
CY1117928T1 (el) 2017-05-17
ZA200410154B (en) 2005-12-28
DK2314591T3 (da) 2014-09-22
PT1567529E (pt) 2014-09-09
PL215151B1 (pl) 2013-10-31
ES2503551T5 (es) 2021-10-28
SI2314591T1 (sl) 2014-11-28
PT2767539T (pt) 2017-08-28
SI1567529T1 (sl) 2014-11-28
EP2314591B1 (en) 2014-06-18
NO331477B1 (no) 2012-01-16
AU2003271740A1 (en) 2003-12-31
EA007120B1 (ru) 2006-06-30
CY1115665T1 (el) 2017-01-25
US10000504B2 (en) 2018-06-19
US20100204316A1 (en) 2010-08-12
AP2052A (en) 2009-10-05
EP1567529B2 (en) 2021-02-24
EA007120B8 (ru) 2012-03-30
CA2485834C (en) 2007-07-17
EA200401503A1 (ru) 2005-06-30
US8518987B2 (en) 2013-08-27
US20130303790A1 (en) 2013-11-14
US20170260196A1 (en) 2017-09-14
KR20050008715A (ko) 2005-01-21
HRP20041061A2 (en) 2006-07-31
IL165140A0 (en) 2005-12-18
PT2314591E (pt) 2014-09-19
EP1567529A2 (en) 2005-08-31
KR101128370B1 (ko) 2012-04-23
US20180312517A1 (en) 2018-11-01
HUE034389T2 (en) 2018-02-28
MXPA04011427A (es) 2005-02-17
ES2498370T5 (es) 2021-11-24
CA2485834A1 (en) 2003-12-24
JP2005533068A (ja) 2005-11-04
EP2767539B1 (en) 2017-07-12
WO2003106461A2 (en) 2003-12-24
BRPI0311176B1 (pt) 2019-08-20
EP1567529B1 (en) 2014-06-18
US10858369B2 (en) 2020-12-08
US20150336980A1 (en) 2015-11-26
CY1119311T1 (el) 2018-02-14
DK2767539T3 (en) 2017-09-11
SI2314591T2 (sl) 2021-08-31
ES2498370T3 (es) 2014-09-24
ES2503551T3 (es) 2014-10-07
US20210179631A1 (en) 2021-06-17
NZ536497A (en) 2006-08-31
SI1567529T2 (sl) 2021-08-31
EP2767539A1 (en) 2014-08-20
EP3045460B1 (en) 2019-04-17
US7700645B2 (en) 2010-04-20
PL374321A1 (en) 2005-10-17
EP3045460A1 (en) 2016-07-20
JP4864320B2 (ja) 2012-02-01
CN100475819C (zh) 2009-04-08
AU2003271740B2 (en) 2010-05-13
ES2638412T3 (es) 2017-10-20
BRPI0311176B8 (pt) 2021-05-25
LT2767539T (lt) 2017-09-25
CN1668623A (zh) 2005-09-14
HRP20041061B1 (hr) 2015-02-27
KR20100119906A (ko) 2010-11-11
AU2012205289A1 (en) 2012-08-09
US20140171499A1 (en) 2014-06-19
DK1567529T4 (da) 2021-05-10

Similar Documents

Publication Publication Date Title
BR0311176A (pt) Formas pseudopolimórficas de um inibidor da protease do hiv
CY1109379T1 (el) Διεργασια για την παρασκευη (3r,3αs,6αr)-εξαϋδροφουρο [2,3-β] φουραν-3-υλ (1s,2r)-3-[[(4-αμινοφαινυλ) σουλφονυλ] (ισοβουτυλ) αμινο]-1-βενζυλ-2-υδροξυπροπυλκαρβαμικου
ME01059B (me) Proces za pripremanje (3r,3as,6ar)-heksahidrofuro [2,3-b] furan-3-il (1s,2r)-3-[[(4-aminofenil) sulfonil] (izobutil) amino]-1-benzil-2- hidroksipropilkarbamata
AR119702A2 (es) Proceso para la preparación de (1s,2r)-3-[[(4-aminofenil)sulfonil](isobutil)amino]-1-bencil-2-hidroxipropilcarbamato de (3r,3as,6ar)-hexahidrofuro[2,3-b]furan-3-ilo
BR0212443A (pt) Sìntese de anéis bicìclicos fundidos, amino substituìdos enanciomericamente puros
EA200100053A1 (ru) Кальций (3s)тетрагидро-3-фуранил(1s,2r)-3-[[(4-аминофенил)сульфонил](изобутил)амино]-1-бензил-2-(фосфоноокси)пропилкарбамат
IL198270A0 (en) Methods for the preparation of hexahydrofuro[2,3-b]furan-3-ol
BR0212341A (pt) Processo para a preparação de hexaidro-furo[2,3-b]furan-3-ol
NO20064977L (no) Fremgangsmater for fremstilling av (3R,3aS,6aR)-heksahydro-furo[2,3-b]furan-3-ol
BR112012009956A2 (pt) um novo processo para a preparação de darunavir e etanolato darunavir de tamanho de partícula.
WO2001000635A3 (en) Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate
WO2005000249A3 (en) Preparation of chemical compounds
BRPI0611954A2 (pt) processos para a produÇço de compostos de anel fundido policÍclico
TW200716948A (en) Micro gyroscope

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: TIBOTEC PHARMACEUTICALS LTD. (IE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070001806/RJ DE 05/01/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 493/04, A61P 31/00

Ipc: C07D 493/04 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/05/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.003778/2023-46 ORIGEM: 7A VARA FEDERAL CIVEL DA SJDF PROCESSO NO: 1014637-50.2023.4.01.3400 ACAO PELO PROCEDIMENTO COMUM COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: JANSSEN SCIENCES IRELAND UC REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.003778/2023-46 SECAO JUDICIARIA DO DISTRITO FEDERAL PROCESSO JUDICIAL: 1014637-50.2023.4.01.3400 AUTOR: JANSSEN SCIENCES IRELAND UC REUS: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI E OUTROS SENTENCA: PUBLICAR QUE O PRAZO DE VIGENCIA DA PATENTE OBJETO DESTA ACAO - PI0311176- 8 - ESTA SUB JUDICE, TANTO NA REVISTA DE PROPRIEDADE INDUSTRIAL, QUANTO NO STATUS DA RESPECTIVA PATENTE NO SITIO DO INPI NA INTERNET (ART. 59, INCISO II, 60 E 226 DA LPI.